<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401257</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-PXT3003-01</org_study_id>
    <nct_id>NCT01401257</nct_id>
  </id_info>
  <brief_title>Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A</brief_title>
  <official_title>A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharnext SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharnext SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial is a randomized, placebo-controlled study evaluating 3 different doses of
      PXT3003 in patients with CMT1A disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to the safety and tolerability of the treatment, clinical, electrophysiological
      and biological endpoints (PMP22 mRNA, skin biopsy histology and plasma biomarkers) will be
      assessed. Standard laboratory tests and drug plasma concentrations will also be measured.
      Because of the slow progression of the disease and the nature of the observed symptoms, a
      minimum duration of 12 months of treatment is required in order to observe a potential
      improvement in any of the efficacy parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of PXT3003</measure>
    <time_frame>Screening, randomization, 1-, 3-, 6-, 9-, 12-month treatment and 1-month follow-up</time_frame>
    <description>The Primary Objective is to assess the clinical and laboratory safety and tolerability of three doses of PXT3003 administered orally for 12 months to CMT1A patients versus placebo.
Number of participants with adverse events in each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Obtain Preliminary Data on the Efficacy of PXT3003 on Clinical Scores and Functional Tests</measure>
    <time_frame>Screening, randomization, 3-, 6-, 9- and 12-months treatment</time_frame>
    <description>Efficacy scores and functional tests will be assessed CMTNS/CMTES:ONLS, VAS, fatigue, pain, six minute walk test (6MWT), nine-hole peg test, quantified muscular testing (QMT; hand grip and foot dorsiflexion), CGI.
For each test or score, change from baseline after 3-,6-, 9- and 12-months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Pharmacodynamic Effect of PXT3003 on PMP22 mRNA Levels and Intra-epidermal Axon Density in Cutaneous Biopsy</measure>
    <time_frame>Randomization and 12-month treatment</time_frame>
    <description>A cutaneous biopsy (consisting in 2 small punch biopsies) will be performed to assess PMP22 mRNA expression and intra-epidermal axon density.
Change from baseline after 12-month of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Pharmacodynamic Effect of PXT3003 on Selected Neurophysiological Parameters</measure>
    <time_frame>Screening, randomization, 3-, 6-, 9- and 12-month treatment</time_frame>
    <description>Electrophysiological examination will be performed to assess sensory and motor responses of the median and ulnar nerves (non-dominant side) including: NCV, compound muscle action potential (CMAP) and SNAP.
Change from baseline after 3-,6-, 9- and 12-months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Pharmacodynamic Effect of PXT3003 on a Series of Biochemical Biomarkers</measure>
    <time_frame>Randomization and 3-month treatment</time_frame>
    <description>Dosages of biochemical biomarkers in plasma.
Change from baseline after 3-month of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Plasma Concentrations of PXT3003</measure>
    <time_frame>Randomization, 1-, 6- and 12-month treatment</time_frame>
    <description>PXT3003 plasmatic concentrations after one administration (randomization) and after 1-,6-and 12-months of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Charcot-Marie-Tooth Disease</condition>
  <condition>Hereditary Neuropathy With Liability to Pressure Palsies</condition>
  <condition>Genetic Disorders</condition>
  <arm_group>
    <arm_group_label>PXT3003 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Liquid formulation, 1/100, bid, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT3003 Intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Liquid formulation, 1/50, bid, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT3003 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Liquid formulation, 1/10, bid, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Liquid formulation, bid, 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003 Low dose</intervention_name>
    <description>Liquid,5 ml, twice a day, 12-month treatment</description>
    <arm_group_label>PXT3003 Low dose</arm_group_label>
    <other_name>Pleocompound PXT3003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003 Intermediate Dose</intervention_name>
    <description>Liquid,5 ml, twice a day, 12-month treatment</description>
    <arm_group_label>PXT3003 Intermediate dose</arm_group_label>
    <other_name>Pleocompound PXT3003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT3003 High Dose</intervention_name>
    <description>Liquid,5 ml, twice a day, 12-month treatment</description>
    <arm_group_label>PXT3003 High dose</arm_group_label>
    <other_name>Pleocompound PXT3003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Liquid,5 ml, twice a day, 12-month treatment</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Pleocompound PXT3003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DNA proven CMT1A

          -  Muscle weakness in at least foot dorsiflexion (clinical assessment)

          -  Age between 18 and 65 years

          -  Male or non pregnant, non breastfeeding female

          -  CMT neuropathy score at screening ≤ 20

          -  Agrees to perform electrorophysiological studies and two cutaneous biopsies for
             determination of PMP22 expression and histology

          -  Providing signed written informed consent to participate in the study and willing and
             able to comply with all study procedures and scheduled visits

        Exclusion Criteria:

          -  Patients with another neurological disease

          -  Patients using unauthorized concomitant treatments, ascorbic acid, opioids,
             levothyroxine and potentially neurotoxic drugs. Patients who can/agree to stop these
             medications 4 weeks before randomization can be included

          -  Patients who have participated in another trial of investigational drug within the
             past 30 days

          -  Concomitant major systemic disease

          -  Clinically significant history of unstable medical illness over the last 30 days
             (unstable angina…)

          -  History of significant hematologic, kidney, liver disease, or insulin-dependent
             diabetes

          -  Clinically significant abnormalities on the prestudy laboratory evaluation, physical
             evaluation, electrocardiogram (ECG)

          -  ASAT/ALAT levels above the upper limit of normal (ULN). However, patients with an
             isolated elevation of either ASAT or ALAT (&lt;1.5 ULN) can be included at investigators‟
             discretion if the remaining liver function tests are normal and if ASAT or ALAT value
             is stable at 2 distinct evaluations in the month prior to inclusion

          -  Serum creatinine levels above the upper limit of normal

          -  Limited mental capacity or psychiatric disease rendering the subject unable to provide
             written informed consent or comply with evaluation procedures

          -  History of recent alcohol or drug abuse or non-adherence with treatment or other
             experimental protocols

          -  Female of childbearing potential (apart of patient using adequate contraceptive
             measures), pregnant or breast feeding

          -  Suspected inability to complete the study follow-up (foreign workers, transient
             visitors, tourists or any others for whom follow-up evaluation is not assured)

          -  Limb surgery in the six months before randomization or planned before completion of
             the trial

          -  Known hypersensitivity to any of the individual components of PXT3003

          -  Porphyria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahram ATTARIAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital La Timone</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Viviane BERTRAND, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pharnext SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2011</study_first_submitted>
  <study_first_submitted_qc>July 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2011</study_first_posted>
  <results_first_submitted>December 23, 2016</results_first_submitted>
  <results_first_submitted_qc>December 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2017</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PXT3003</keyword>
  <keyword>Charcot-Marie-Tooth Disease</keyword>
  <keyword>Hereditary Motor and Sensory Neuropathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PXT3003 Low Dose</title>
          <description>Oral Liquid formulation, 1/100, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="P2">
          <title>PXT3003 Intermediate Dose</title>
          <description>Oral Liquid formulation, 1/50, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="P3">
          <title>PXT3003 High Dose</title>
          <description>Oral Liquid formulation, 1/10, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Oral Liquid formulation, bid, 12 months
Placebo: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PXT3003 Low Dose</title>
          <description>Oral Liquid formulation, 1/100, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="B2">
          <title>PXT3003 Intermediate Dose</title>
          <description>Oral Liquid formulation, 1/50, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="B3">
          <title>PXT3003 High Dose</title>
          <description>Oral Liquid formulation, 1/10, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Oral Liquid formulation, bid, 12 months
Placebo: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" lower_limit="18" upper_limit="63"/>
                    <measurement group_id="B2" value="44.3" lower_limit="23" upper_limit="64"/>
                    <measurement group_id="B3" value="44.6" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="B4" value="43.2" lower_limit="21" upper_limit="65"/>
                    <measurement group_id="B5" value="45.1" lower_limit="18" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of PXT3003</title>
        <description>The Primary Objective is to assess the clinical and laboratory safety and tolerability of three doses of PXT3003 administered orally for 12 months to CMT1A patients versus placebo.
Number of participants with adverse events in each arm.</description>
        <time_frame>Screening, randomization, 1-, 3-, 6-, 9-, 12-month treatment and 1-month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PXT3003 Low Dose</title>
            <description>Oral Liquid formulation, 1/100, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
          </group>
          <group group_id="O2">
            <title>PXT3003 Intermediate Dose</title>
            <description>Oral Liquid formulation, 1/50, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
          </group>
          <group group_id="O3">
            <title>PXT3003 High Dose</title>
            <description>Oral Liquid formulation, 1/10, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Oral Liquid formulation, bid, 12 months
Placebo: Liquid,5 ml, twice a day, 12-month treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of PXT3003</title>
          <description>The Primary Objective is to assess the clinical and laboratory safety and tolerability of three doses of PXT3003 administered orally for 12 months to CMT1A patients versus placebo.
Number of participants with adverse events in each arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Obtain Preliminary Data on the Efficacy of PXT3003 on Clinical Scores and Functional Tests</title>
        <description>Efficacy scores and functional tests will be assessed CMTNS/CMTES:ONLS, VAS, fatigue, pain, six minute walk test (6MWT), nine-hole peg test, quantified muscular testing (QMT; hand grip and foot dorsiflexion), CGI.
For each test or score, change from baseline after 3-,6-, 9- and 12-months of treatment.</description>
        <time_frame>Screening, randomization, 3-, 6-, 9- and 12-months treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Pharmacodynamic Effect of PXT3003 on PMP22 mRNA Levels and Intra-epidermal Axon Density in Cutaneous Biopsy</title>
        <description>A cutaneous biopsy (consisting in 2 small punch biopsies) will be performed to assess PMP22 mRNA expression and intra-epidermal axon density.
Change from baseline after 12-month of treatment.</description>
        <time_frame>Randomization and 12-month treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Pharmacodynamic Effect of PXT3003 on Selected Neurophysiological Parameters</title>
        <description>Electrophysiological examination will be performed to assess sensory and motor responses of the median and ulnar nerves (non-dominant side) including: NCV, compound muscle action potential (CMAP) and SNAP.
Change from baseline after 3-,6-, 9- and 12-months of treatment.</description>
        <time_frame>Screening, randomization, 3-, 6-, 9- and 12-month treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Pharmacodynamic Effect of PXT3003 on a Series of Biochemical Biomarkers</title>
        <description>Dosages of biochemical biomarkers in plasma.
Change from baseline after 3-month of treatment.</description>
        <time_frame>Randomization and 3-month treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Plasma Concentrations of PXT3003</title>
        <description>PXT3003 plasmatic concentrations after one administration (randomization) and after 1-,6-and 12-months of treatment.</description>
        <time_frame>Randomization, 1-, 6- and 12-month treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PXT3003 Low Dose</title>
          <description>Oral Liquid formulation, 1/100, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="E2">
          <title>PXT3003 Intermediate Dose</title>
          <description>Oral Liquid formulation, 1/50, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="E3">
          <title>PXT3003 High Dose</title>
          <description>Oral Liquid formulation, 1/10, bid, 12 months
PXT3003: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Oral Liquid formulation, bid, 12 months
Placebo: Liquid,5 ml, twice a day, 12-month treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <description>Unrelated to study medication.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <description>Unrelated to study medication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No individual publication (paper, abstract, poster, oral presentation) is allowed until results of the complete study have been published.
The Investigator agrees that any proposed publication, presentation or use of results arising from the Investigation will be submitted to Pharnext for review and written agreement prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr Shahram ATTARIAN</name_or_title>
      <organization>Hôpital La Timone, Marseille</organization>
      <phone>04 91 38 65 ext 79</phone>
      <email>shahram.attarian@ap-hm.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

